SYMBYX is an Australian med-tech company that develops laser light therapy devices to promote wellness and help manage symptoms of chronic conditions. For example, Parkinson's, Fibromyalgia, IBD/IBS, Arthritis, Chronic Pain and more. We take a customer-focused approach to improve quality of life for those with chronic illness, using non-pharmaceutical methods.

Founded in 2019 by a diverse group of consumer, medical and biotech professionals, we are a privately-held, early-stage company with partners and investors in the US, Sweden, Germany and Australia. 

Our medical grade devices use photobiomodulation (low-level laser light therapy) to stimulate cell recovery and reduce chronic pain and inflammation, often via the gut microbiome and the gut-brain axis, but also via the brain directly. 

We take pride in the fact that we are a research-backed company. For example, please see clinical trial results published in BMC Neurology Journal on 2 July 2021, "Improvements in clinical signs of Parkinson's disease using photobiomodulation." Patients showed significant improvements in cognition, movement and mood, and have sustained those improvements for over 3 years now. We are currently involved in large-scale randomised, placebo control, scientific trials in Canada and Australia, and in discussion with several further universities and prominent photobiomodulation researchers. 

Our products are CE/ARTG listed and backed by a team of qualified clinicians worldwide who work with customers directly and also, made in Sweden and Australia, and come with a 1 year warranty. 

SYMBYX devices are subject to different regulations, permits and clearances in each country and are not available for sale in all countries, including the U.S.

SYMBYX Biome

Org chart

Teams

Offices